ChristensenRJollyAYamC, et al. Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler J2024; 31: 218–230.
2.
Cerdá-FuertesNStoesselMMickeliunasG, et al. Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis. Mult Scler2023; 29(13): 1540–1550.
3.
CordanoCNourbakhshBYiuHH, et al. Differences in age-related retinal and cortical atrophy rates in multiple sclerosis. Neurology2022; 99: e1685–e1693.
4.
BstehGHegenHAltmannP, et al. Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. Eur J Neurol2021; 28(6): 2037–2045.
5.
BstehGHegenHTeuchnerB, et al. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler J2017; 25: 196–203.
6.
RatchfordJNQuiggMECongerA, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology2009; 73: 302–308.
7.
CordanoCWerneburgSAbdelhakA, et al. Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis. Cell Rep Med2024; 5: 101490.
